Tamoxifen for retroperitoneal fibrosis
1Katharine House Hospice, East End, Adderbury, Oxon, OX17 3NL, UK. dr.ch@mbers.info
Palliative Medicine
|April 7, 2005
Summary
Retroperitoneal fibrosis, an inflammatory condition, can cause fatal ureter blockage. Tamoxifen therapy showed promise in improving renal function and treating associated lymphoedema in a case study.
Area of Science:
- Nephrology
- Oncology
- Immunology
Background:
- Retroperitoneal fibrosis involves inflammatory fibroblast proliferation and collagen deposition in the retroperitoneum.
- This condition can obstruct ureters, vasculature, and lymphatic channels, leading to a progressive, fatal course if untreated.
Observation:
- Tamoxifen has shown positive responses in retroperitoneal fibrosis cases, with reported improvements in renal function.
- This report details a patient experiencing subjective and objective functional improvement in lymphoedema secondary to retroperitoneal fibrosis.
Findings:
- Tamoxifen treatment led to both patient-reported and measurable functional gains in lymphoedema.
- The study highlights tamoxifen's potential beyond renal function improvement in managing retroperitoneal fibrosis complications.
Implications:
- Tamoxifen may be a viable therapeutic option for managing lymphoedema associated with retroperitoneal fibrosis.
- Further research into tamoxifen's efficacy for lymphoedema in retroperitoneal fibrosis is warranted.
More Related Videos
07:38A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
Published on: April 13, 2018
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019